The goal of this observational multicenter feasibility and implementation study is to evaluate home-based treatment with intravenous Cytarabine for patients with acute myeloid leukemia in Denmark. The study aims to generate research-based evidence on feasibility, safety, patient impact, health economic costs, and implementation of home-based intravenous chemotherapy treatment. The main questions it aims to answer are: 1\. What is the existing evidence on home-based chemotherapy treatment for patients with hematological malignancies, including feasibility, safety, symptoms, quality of life, and cost-effectiveness? 2\. Is home-based treatment with intravenous Cytarabine feasible and safe for patients with acute myeloid leukemia in Denmark? 3\. What are the costs, patient-reported outcomes, and caregiver roles related to home-based Cytarabine treatment? 4\. What are the key barriers and facilitators experienced by patients, caregivers, and healthcare professionals during home-based Cytarabine treatment? Which national strategies and recommendations can support the implementation, scalability, sustainability, and equitable access to home-based intravenous Cytarabine treatment across healthcare settings in Denmark?

Trial Details

NCT Number	NCT07802015
Lead Sponsor	Zealand University Hospital Collaborators: Rigshospitalet, Denmark, Odense University Hospital
Conditions (from sponsor)	Hematologic Cancer, Acute Myeloid Leukaemia (AML), Hospital At Home, Home-based Chemotherapy
Related terms	Hematologic Neoplasms, Leukemia, Myeloid, Acute
Enrollment	80 participants
Start Date	Aug 17, 2026
Primary Completion	Dec 30, 2027 (estimated)
Study Completion	Jan 30, 2029 (estimated)
Updated on ClinicalTrials.gov	Sep 3, 2026